These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 31583566)

  • 1. Development and verification of a three-dimensional (3D) breast cancer tumor model composed of circulating tumor cell (CTC) subsets.
    Anil-Inevi M; Sağlam-Metiner P; Kabak EC; Gulce-Iz S
    Mol Biol Rep; 2020 Jan; 47(1):97-109. PubMed ID: 31583566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer.
    Hyun KA; Koo GB; Han H; Sohn J; Choi W; Kim SI; Jung HI; Kim YS
    Oncotarget; 2016 Apr; 7(17):24677-87. PubMed ID: 27013581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The isolation and characterization of CTC subsets related to breast cancer dormancy.
    Vishnoi M; Peddibhotla S; Yin W; T Scamardo A; George GC; Hong DS; Marchetti D
    Sci Rep; 2015 Dec; 5():17533. PubMed ID: 26631983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics.
    Chen W; Allen SG; Reka AK; Qian W; Han S; Zhao J; Bao L; Keshamouni VG; Merajver SD; Fu J
    BMC Cancer; 2016 Aug; 16():614. PubMed ID: 27501846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
    Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
    Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
    [No Abstract]   [Full Text] [Related]  

  • 6. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
    Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
    Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles.
    Wang G; Benasutti H; Jones JF; Shi G; Benchimol M; Pingle S; Kesari S; Yeh Y; Hsieh LE; Liu YT; Elias A; Simberg D
    Colloids Surf B Biointerfaces; 2018 Jan; 161():200-209. PubMed ID: 29080504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
    Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
    Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A biosensor capable of identifying low quantities of breast cancer cells by electrical impedance spectroscopy.
    Huerta-Nuñez LFE; Gutierrez-Iglesias G; Martinez-Cuazitl A; Mata-Miranda MM; Alvarez-Jiménez VD; Sánchez-Monroy V; Golberg A; González-Díaz CA
    Sci Rep; 2019 Apr; 9(1):6419. PubMed ID: 31015522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells.
    Nini A; Hoffmann MJ; Lampignano R; Große Siemer R; van Dalum G; Szarvas T; Cotarelo CL; Schulz WA; Niederacher D; Neubauer H; Stoecklein NH; Niegisch G
    Cytometry B Clin Cytom; 2020 Jul; 98(4):355-367. PubMed ID: 32212383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
    Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
    Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S
    Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of different CTC subpopulations in non-small cell lung cancer.
    Hanssen A; Wagner J; Gorges TM; Taenzer A; Uzunoglu FG; Driemel C; Stoecklein NH; Knoefel WT; Angenendt S; Hauch S; Atanackovic D; Loges S; Riethdorf S; Pantel K; Wikman H
    Sci Rep; 2016 Jun; 6():28010. PubMed ID: 27302574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
    Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
    J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biomarker analyses using circulating tumor cells.
    Punnoose EA; Atwal SK; Spoerke JM; Savage H; Pandita A; Yeh RF; Pirzkall A; Fine BM; Amler LC; Chen DS; Lackner MR
    PLoS One; 2010 Sep; 5(9):e12517. PubMed ID: 20838621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.
    Galletti G; Sung MS; Vahdat LT; Shah MA; Santana SM; Altavilla G; Kirby BJ; Giannakakou P
    Lab Chip; 2014 Jan; 14(1):147-56. PubMed ID: 24202699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
    Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT
    PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.